People at a higher risk of B12 deficiencies include older adults, people who suffer from gastrointestinal disorders or have had gastrointestinal surgeries, and anyone who adheres to a vegan or vegetarian diet
Filed Under: Biologics, Dermatology, Immunology, Infectious Disease, Metabolic disease/endicrinology, Oncology Tagged With: AbbVie, biologic drugs, biosimilar competition, drug sales H1 2025, Eli Lilly, GLP-1 drugs, IL-23 inhibitors, immunology drugs, Keytruda patent expiry, loss of exclusivity, Merck, Novo Nordisk, obesity drugs, Oncology Therapeutics, patent cliff 2028, PD-1 inhibitors, pharmaceutical blockbusters, prescription drug market, Skyrizi, therapeutic categories Brian Buntz As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology
GLP3-R GLP1-S Safety and Side Effects in Research In controlled studies, GLP1-S has generally been well-tolerated , though gastrointestinal events are among the most common findings
There are some studies which show promise, but its not a quick fix. Sign up for our Health Essentials emails for expert guidance on nutrition, fitness, sleep, skin care and more
Strip those away and you are left with the list price, which is where the confusion starts
I just ordered my second and moved up slightly in dosage After a lot of research, Im so glad I chose VitaSTIR for my journey
